Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study

BACKGROUND: Moxifloxacin is a second-line anti-TB drug that is useful in the treatment of drug-resistant TB. However, little is known about its target site pharmacokinetics. Lower drug concentrations at the infection site (i.e. in severe lung lesions including cavitary lesions) may lead to developme...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Antimicrob Chemother
Autors principals: Heinrichs, M Tobias, Vashakidze, Sergo, Nikolaishvili, Ketino, Sabulua, Irina, Tukvadze, Nestani, Bablishvili, Nino, Gogishvili, Shota, Little, Brent P, Bernheim, Adam, Guarner, Jeannette, Peloquin, Charles A, Blumberg, Henry M, Derendorf, Hartmut, Kempker, Russell R
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890684/
https://ncbi.nlm.nih.gov/pubmed/29186509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkx421
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars